CBLI - Cleveland BioLabs, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue3,518.4022,708.2253,701.899
Cost of Revenue---
Gross Profit3,518.4022,708.2253,701.899
Operating Expenses
Research Development6,496.1227,143.2939,654.144
Selling General and Administrative3,378.136,355.9628,469.69
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-6,355.85-10,791.03-14,421.935
Income from Continuing Operations
Total Other Income/Expenses Net3,502.138-1,792.26215,832.425
Earnings Before Interest and Taxes-2,590.059-12,682.78320.908
Interest Expense---
Income Before Tax-2,590.059-12,682.78320.908
Income Tax Expense---
Minority Interest5,322.8115,149.673,393.499
Net Income From Continuing Ops-2,658.865-12,637.6371,629.104
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-2,658.865-12,637.6371,629.104
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-2,658.865-12,637.6371,629.104